DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/r85v6f/quilizumab) has announced the addition of the "Quilizumab (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Roche's quilizumab is an anti-M1 prime humanized mAb designed to eliminate B cells that would otherwise develop into plasma cells and produce IgE. This is a different mechanism from binding to and neutralizing existing IgE, as does Novartis' Xolair. IgE is important in the development of allergic asthma, as it binds to mast cells and basophils, which play a significant role in the pathogenesis of asthma. IgE ultimately triggers the release of histamines, prostaglandins, and leukotrienes, which produce airway inflammation and obstruction. Anti-IgE therapy is designed to block IgE at the beginning of its cascade. Roche is already an established player in the biological segment of the asthma market, and this is its second biological pipeline product entering late-phase development.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Quilizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Quilizumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/r85v6f/quilizumab